| Package | dk.kip.rkkp.fhir.ig.core |
| Type | ValueSet |
| Id | Id |
| FHIR Version | R4 |
| Source | https://kip.rkkp.dk/fhir/https://build.fhir.org/ig/KIP-infrastructure/implementation-guide/ValueSet-TreatmentRegimen.html |
| Url | https://kip.rkkp.dk/fhir/ValueSet/TreatmentRegimen |
| Version | 2.11.0 |
| Status | active |
| Date | 2022-07-13T00:00:00+02:00 |
| Name | TreatmentRegimen |
| Title | Behandlingsplan |
| Experimental | True |
| Description | Behandlingsplan som beskriver specifikke codsering og planlægningen af behandling |
No resources found
| CodeSystem | |
TreatmentRegimen  | Treatment regimen |
Note: links and images are rebased to the (stated) source
Generated Narrative: ValueSet TreatmentRegimen
FHIRhttps://kip.rkkp.dk/fhir/CodeSystem/TreatmentRegimen| Code | Display | Definition |
| hydrea | Hydrea | Hydrea |
| hdara_c | HdAraC | Hd-Ara-c +- supplement |
| da31087 | DA inkl. 3+10, 3+8, 3+7 | DA inkl. 3+10, 3+8, 3+7 |
| da31087my | DA inkl. 3+10, 3+8, 3+7 + mylotarg | DA inkl. 3+10, 3+8, 3+7 + mylotarg |
| da31087mi | DA inkl. 3+10, 3+8, 3+7 + midostaurin | DA inkl. 3+10, 3+8, 3+7 + midostaurin |
| flagmito | FLAG-Ida eller lign inkl FLAG, Mito-FLAG | FLAG-Ida eller lign inkl FLAG, Mito-FLAG |
| flagmitovene | FLAG-Ida eller lign inkl FLAG, Mito-FLAG + venetoclax | FLAG-Ida eller lign inkl FLAG, Mito-FLAG + venetoclax |
| idarac | IdAraC | IdAraC |
| apl_mt | APL vedligehold | APL-vedligeholdsbehandling |
| azacitidinmono | Azacitidin monoterapi | Azacitidin monoterapi |
| blinatumomab | Blinatumunab | Blinatumomab |
| vyxeos | Vyxeos | Vyxeos +- supplement |
| nopho_2008 | NOPHO 2008 | NOPHO-2008 |
| atoatra | ATO+ATRA | ATO+ATRA |
| aida | AIDA | AIDA |
| azacitidinvene | Azacitidin-venetoclax | Azacitidin-venetoclax |
| toplusfem | 2+5 eller lign, eks. CT | 2+5 eller lign, eks. CT |
| gilteritinib | Gilteritinib | Gilteritinib |
| midostaurin_ved | Midostaurin vedligehold | Midostaurin vedligehold |
| inotuzumab | Inotuzumab ozogamicin | Inotuzumab ozogamicin |
| all_ved | ALL vedligehold | ALL vedligehold |
| hyper_cvad | Hyper-CVAD | Hyper-CVAD |
| alltogether_mt | ALLtogether | ALLtogether |
| other_ikke | Anden ikke-intensiv | Anden ikke-intensiv |
| other_eks | Anden eksperimentel | Anden eksperimentel |
| other_semi | Anden semiintensiv (f.eks. Plan B) | Anden semiintensiv (f.eks. Plan B) |
| other_int | Anden intensiv (f.eks. BISHOP, Plan A) | Anden intensiv (f.eks. BISHOP, Plan A) |
{
"resourceType" : "ValueSet",
"id" : "TreatmentRegimen",
"text" : {
"status" : "extensions",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: ValueSet TreatmentRegimen</b></p><a name=\"TreatmentRegimen\"> </a><a name=\"hcTreatmentRegimen\"> </a><a name=\"TreatmentRegimen-en-US\"> </a><ul><li>Include these codes as defined in <a href=\"CodeSystem-TreatmentRegimen.html\"><code>https://kip.rkkp.dk/fhir/CodeSystem/TreatmentRegimen</code></a><table class=\"none\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td><td><b>Definition</b></td></tr><tr><td><a href=\"CodeSystem-TreatmentRegimen.html#TreatmentRegimen-hydrea\">hydrea</a></td><td>Hydrea</td><td>Hydrea</td></tr><tr><td><a href=\"CodeSystem-TreatmentRegimen.html#TreatmentRegimen-hdara_c\">hdara_c</a></td><td>HdAraC</td><td>Hd-Ara-c +- supplement</td></tr><tr><td><a href=\"CodeSystem-TreatmentRegimen.html#TreatmentRegimen-da31087\">da31087</a></td><td>DA inkl. 3+10, 3+8, 3+7</td><td>DA inkl. 3+10, 3+8, 3+7</td></tr><tr><td><a href=\"CodeSystem-TreatmentRegimen.html#TreatmentRegimen-da31087my\">da31087my</a></td><td>DA inkl. 3+10, 3+8, 3+7 + mylotarg</td><td>DA inkl. 3+10, 3+8, 3+7 + mylotarg</td></tr><tr><td><a href=\"CodeSystem-TreatmentRegimen.html#TreatmentRegimen-da31087mi\">da31087mi</a></td><td>DA inkl. 3+10, 3+8, 3+7 + midostaurin</td><td>DA inkl. 3+10, 3+8, 3+7 + midostaurin</td></tr><tr><td><a href=\"CodeSystem-TreatmentRegimen.html#TreatmentRegimen-flagmito\">flagmito</a></td><td>FLAG-Ida eller lign inkl FLAG, Mito-FLAG</td><td>FLAG-Ida eller lign inkl FLAG, Mito-FLAG</td></tr><tr><td><a href=\"CodeSystem-TreatmentRegimen.html#TreatmentRegimen-flagmitovene\">flagmitovene</a></td><td>FLAG-Ida eller lign inkl FLAG, Mito-FLAG + venetoclax</td><td>FLAG-Ida eller lign inkl FLAG, Mito-FLAG + venetoclax</td></tr><tr><td><a href=\"CodeSystem-TreatmentRegimen.html#TreatmentRegimen-idarac\">idarac</a></td><td>IdAraC</td><td>IdAraC</td></tr><tr><td><a href=\"CodeSystem-TreatmentRegimen.html#TreatmentRegimen-apl_mt\">apl_mt</a></td><td>APL vedligehold</td><td>APL-vedligeholdsbehandling</td></tr><tr><td><a href=\"CodeSystem-TreatmentRegimen.html#TreatmentRegimen-azacitidinmono\">azacitidinmono</a></td><td>Azacitidin monoterapi</td><td>Azacitidin monoterapi</td></tr><tr><td><a href=\"CodeSystem-TreatmentRegimen.html#TreatmentRegimen-blinatumomab\">blinatumomab</a></td><td>Blinatumunab</td><td>Blinatumomab</td></tr><tr><td><a href=\"CodeSystem-TreatmentRegimen.html#TreatmentRegimen-vyxeos\">vyxeos</a></td><td>Vyxeos</td><td>Vyxeos +- supplement</td></tr><tr><td><a href=\"CodeSystem-TreatmentRegimen.html#TreatmentRegimen-nopho_2008\">nopho_2008</a></td><td>NOPHO 2008</td><td>NOPHO-2008</td></tr><tr><td><a href=\"CodeSystem-TreatmentRegimen.html#TreatmentRegimen-atoatra\">atoatra</a></td><td>ATO+ATRA</td><td>ATO+ATRA</td></tr><tr><td><a href=\"CodeSystem-TreatmentRegimen.html#TreatmentRegimen-aida\">aida</a></td><td>AIDA</td><td>AIDA</td></tr><tr><td><a href=\"CodeSystem-TreatmentRegimen.html#TreatmentRegimen-azacitidinvene\">azacitidinvene</a></td><td>Azacitidin-venetoclax</td><td>Azacitidin-venetoclax</td></tr><tr><td><a href=\"CodeSystem-TreatmentRegimen.html#TreatmentRegimen-toplusfem\">toplusfem</a></td><td>2+5 eller lign, eks. CT</td><td>2+5 eller lign, eks. CT</td></tr><tr><td><a href=\"CodeSystem-TreatmentRegimen.html#TreatmentRegimen-gilteritinib\">gilteritinib</a></td><td>Gilteritinib</td><td>Gilteritinib</td></tr><tr><td><a href=\"CodeSystem-TreatmentRegimen.html#TreatmentRegimen-midostaurin_ved\">midostaurin_ved</a></td><td>Midostaurin vedligehold</td><td>Midostaurin vedligehold</td></tr><tr><td><a href=\"CodeSystem-TreatmentRegimen.html#TreatmentRegimen-inotuzumab\">inotuzumab</a></td><td>Inotuzumab ozogamicin</td><td>Inotuzumab ozogamicin</td></tr><tr><td><a href=\"CodeSystem-TreatmentRegimen.html#TreatmentRegimen-all_ved\">all_ved</a></td><td>ALL vedligehold</td><td>ALL vedligehold</td></tr><tr><td><a href=\"CodeSystem-TreatmentRegimen.html#TreatmentRegimen-hyper_cvad\">hyper_cvad</a></td><td>Hyper-CVAD</td><td>Hyper-CVAD</td></tr><tr><td><a href=\"CodeSystem-TreatmentRegimen.html#TreatmentRegimen-alltogether_mt\">alltogether_mt</a></td><td>ALLtogether</td><td>ALLtogether</td></tr><tr><td><a href=\"CodeSystem-TreatmentRegimen.html#TreatmentRegimen-other_ikke\">other_ikke</a></td><td>Anden ikke-intensiv</td><td>Anden ikke-intensiv</td></tr><tr><td><a href=\"CodeSystem-TreatmentRegimen.html#TreatmentRegimen-other_eks\">other_eks</a></td><td>Anden eksperimentel</td><td>Anden eksperimentel</td></tr><tr><td><a href=\"CodeSystem-TreatmentRegimen.html#TreatmentRegimen-other_semi\">other_semi</a></td><td>Anden semiintensiv (f.eks. Plan B)</td><td>Anden semiintensiv (f.eks. Plan B)</td></tr><tr><td><a href=\"CodeSystem-TreatmentRegimen.html#TreatmentRegimen-other_int\">other_int</a></td><td>Anden intensiv (f.eks. BISHOP, Plan A)</td><td>Anden intensiv (f.eks. BISHOP, Plan A)</td></tr></table></li></ul></div>"
},
"url" : "https://kip.rkkp.dk/fhir/ValueSet/TreatmentRegimen",
"version" : "2.11.0",
"name" : "TreatmentRegimen",
"title" : "Behandlingsplan",
"status" : "active",
"experimental" : true,
"date" : "2022-07-13T00:00:00+02:00",
"publisher" : "Sundhedsvæsenets Kvalitetsinstitut with Trifork Digital Health A/S",
"contact" : [
{
"name" : "Sundhedsvæsenets Kvalitetsinstitut with Trifork Digital Health A/S",
"telecom" : [
{
"system" : "url",
"value" : "https://trifork.com"
},
{
"system" : "email",
"value" : "rbk@trifork.com"
}
]
}
],
"description" : "Behandlingsplan som beskriver specifikke codsering og planlægningen af behandling",
"compose" : {
"include" : [
{
"system" : "https://kip.rkkp.dk/fhir/CodeSystem/TreatmentRegimen",
"concept" : [
{
"code" : "hydrea",
"display" : "Hydrea"
},
{
"code" : "hdara_c",
"display" : "HdAraC"
},
{
"code" : "da31087",
"display" : "DA inkl. 3+10, 3+8, 3+7"
},
{
"code" : "da31087my",
"display" : "DA inkl. 3+10, 3+8, 3+7 + mylotarg"
},
{
"code" : "da31087mi",
"display" : "DA inkl. 3+10, 3+8, 3+7 + midostaurin"
},
{
"code" : "flagmito",
"display" : "FLAG-Ida eller lign inkl FLAG, Mito-FLAG"
},
{
"code" : "flagmitovene",
"display" : "FLAG-Ida eller lign inkl FLAG, Mito-FLAG + venetoclax"
},
{
"code" : "idarac",
"display" : "IdAraC"
},
{
"code" : "apl_mt",
"display" : "APL vedligehold"
},
{
"code" : "azacitidinmono",
"display" : "Azacitidin monoterapi"
},
{
"code" : "blinatumomab",
"display" : "Blinatumunab"
},
{
"code" : "vyxeos",
"display" : "Vyxeos"
},
{
"code" : "nopho_2008",
"display" : "NOPHO 2008"
},
{
"code" : "atoatra",
"display" : "ATO+ATRA"
},
{
"code" : "aida",
"display" : "AIDA"
},
{
"code" : "azacitidinvene",
"display" : "Azacitidin-venetoclax"
},
{
"code" : "toplusfem",
"display" : "2+5 eller lign, eks. CT"
},
{
"code" : "gilteritinib",
"display" : "Gilteritinib"
},
{
"code" : "midostaurin_ved",
"display" : "Midostaurin vedligehold"
},
{
"code" : "inotuzumab",
"display" : "Inotuzumab ozogamicin"
},
{
"code" : "all_ved",
"display" : "ALL vedligehold"
},
{
"code" : "hyper_cvad",
"display" : "Hyper-CVAD"
},
{
"code" : "alltogether_mt",
"display" : "ALLtogether"
},
{
"code" : "other_ikke",
"display" : "Anden ikke-intensiv"
},
{
"code" : "other_eks",
"display" : "Anden eksperimentel"
},
{
"code" : "other_semi",
"display" : "Anden semiintensiv (f.eks. Plan B)"
},
{
"code" : "other_int",
"display" : "Anden intensiv (f.eks. BISHOP, Plan A)"
}
]
}
]
}
}
XIG built as of ??metadata-date??. Found ??metadata-resources?? resources in ??metadata-packages?? packages.